Benralizumab Reduces Asthma Worsening Episodes

Abstract:

Rationale: CompEx (Composite Endpoint for Exacerbations) was recently proposed as a novel endpoint of acute asthma worsening (Lancet Respir Med 2017; 5: 577-90). CompEx is captured when patients experience a severe exacerbation (SevEx) or asthma worsening episode (AWE), as defined by change in peak expiratory flow, reliever medication use, and asthma symptoms captured in daily diaries. Our objective was to evaluate the effect of benralizumab on CompEx and its separate components (SevEx and AWE). Methods: This was a post-hoc analysis of the Phase III SIROCCO (NCT01928771; Lancet 2016; 388: 2115-27) and CALIMA (NCT01914757; Lancet 2016; 388: 2128-41) trials. Included patients were≥ 16 years old with baseline blood eosinophil counts≥ 300 cells/µL (N= 1,039) who received benralizumab 30 mg or placebo every 8 weeks (first three doses every 4 weeks). For CompEx and its …

Año de publicación:

2019

Keywords:

Fuente:

google